terconazole

Trade name: terazol

Small moleculeapproved

Approved

Dec 31, 1987

Terconazole is an antifungal drug used to treat vaginal yeast infection. Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 "14-alpha-demethylase" in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth. During controlled clinical studies conducted in the United States, 521 patients with vulvovaginal candidiasis were treated with terconazole 0.4% vaginal cream. Based on comparative analyses with placebo, the adverse experiences considered most likely related to terconazole 0.4% vaginal cream were a headache and body pain. Fever and chills, vulvovaginal burning, itching, and irritation have also been reported. The adverse drug experience on terconazole most frequently causing discontinuation was vulvovaginal itching. — NCATS

Clinical trial activity

7 trials · 8 clinical orgs · 7 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
4
Phase 4
1

Earliest trial started Dec 1, 2002 (NCT00803738)

Timeline

1980s

  1. Dec 31, 1987

    Earliest FDA Approval

  2. Dec 31, 1987

    Johnson and Johnson — NDA Secondary Org

2000s

  1. Apr 6, 2004

    Taro Pharmaceuticals — Marketing Organization

  2. Oct 1, 2004

    Altana — First NDA Organization

  3. Oct 1, 2004

    Nycomed — NDA Secondary Org

  4. Oct 1, 2004

    Fougera — NDA Secondary Org

  5. Oct 1, 2004

    Altana — NDA Organization

  6. Feb 18, 2005

    Fougera — Marketing Organization

  7. Mar 17, 2006

    Perrigo — Marketing Organization

  8. Mar 17, 2006

    Padagis Us — Marketing Organization

  9. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  10. Jan 1, 2007

    Johnson and Johnson — Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 31, 1987

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)N1CCN(CC1)C2=CC=C(OC[C@@H]3CO[C@](CN4C=NC=N4)(O3)C5=CC=C(Cl)C=C5Cl)C=C2
Mol. weight
532.462 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1-(4-((2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine
  • cilag brand of terconazole
  • fungistat
  • fungistat
  • fungistat
  • gyno-terazol
  • gyno-terazol
  • gyno-terazol
  • janssen brand of terconazole
  • ortho brand of terconazole
  • panlomyc
  • panlomyc
  • r 42470
  • r-42470
  • r-42470
  • r-42470
  • terazol
  • terazol
  • terazol
  • terazol
  • terazol
  • terazol
  • terazol 3
  • terazol 3
  • terazol 7
  • terazol 7
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • terconazole
  • termayazole
  • triaconazole
  • triaconazole
  • triaconazole

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03473418Phase 3Apr 1, 2018Assiut University
NCT02308007Phase 3Jun 1, 2015Curatek Pharmaceuticals
NCT02308046Phase 3Jun 1, 2015Curatek Pharmaceuticals
NCT02180100Phase 4Aug 1, 2013Peking University, Shanghai Shyndec Pharmaceutical Co.,Ltd.
NCT01867164Phase 3Dec 1, 2007Johnson and Johnson
NCT00503542Early Phase 1 (Phase 1)Feb 1, 2007Department of Health and Human Services, Yeshiva University
NCT00803738N/ADec 1, 2002Perrigo
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Curatek PharmaceuticalsFor profit2212015
Assiut UniversityAcademic/Hospital1112018
Department of Health and Human ServicesGovernment1112007
Johnson and JohnsonFor profit1112007
Peking UniversityAcademic/Hospital1112013
PerrigoFor profit1112002
Shanghai Shyndec Pharmaceutical Co.,Ltd.For profit1012013
Yeshiva UniversityAcademic/Hospital1012007
8 organizations
Page 1 / 1

Marketing (9)

OrganizationOrg typeRelationshipDate
AltanaFor profitNDAOct 1, 2004
FougeraFor profitMKTGFeb 18, 2005
FougeraFor profitNDA2Oct 1, 2004
Johnson and JohnsonFor profitNDA2Dec 31, 1987
NycomedFor profitNDA2Oct 1, 2004
Padagis UsFor profitMKTGMar 17, 2006
PerrigoFor profitMKTGMar 17, 2006
PerrigoFor profitSYNMar 17, 2006
Taro PharmaceuticalsFor profitMKTGApr 6, 2004